The RDIF (Russian Direct Investment Fund) and the Gamaleia National Research Center for Epidemiology and Microbiology announced on Wednesday that the single-dose Sputnik Light vaccine demonstrates 70% efficacy against delta-variant infection during the first 3 months. The Sputnik Light vaccine is based on human adenovirus serotype 26, the first component of Sputnik V. The vaccine is 75% effective among people under 60 years of age.
According to the Gamaleia Center, Sputnik Light demonstrated superior efficacy compared to some foreign two-dose vaccines, which showed a large decline in efficacy against the delta variant to less than 50% 5 months after application.
+ French study confirms efficacy of vaccines against covid-19
The vaccine will be produced in India, China, South Korea, Vietnam, Mexico, Argentina, Serbia and Turkey. It has already been authorized in more than 15 countries, with the registration process underway in another 30 – Brazil is not one of them.
“The delta variant of coronavirus is one of the most common and dangerous strains. Data analysis by the Gamaleia Center demonstrates that Sputnik Light remains highly effective months after vaccination. The results obtained during the study significantly surpass those of some other vaccines, as previously published in the scientific media”, said the assistant director of the Gamaleia Center, Denis Logunov.
“The vaccine’s single-dose regimen makes it a strong solution for countries with low vaccination rates. Sputnik Light can also be used successfully to maintain existing herd immunity as a booster injection,” he added.
Sputnik Light as a booster dose
The Gamaleia data also showed that the effectiveness of Sputnik Light as a booster against the delta variant combined with other vaccines will be close to that of the delta variant of the Sputnik V vaccine: more than 83% against infection and more than 94% against hospitalization.
Preliminary results from the combined use of the AstraZeneca and Sputnik Light vaccine from a clinical trial in Azerbaijan demonstrated that antibodies to the spike protein of the SARS-CoV-2 virus (protein S) appeared in 100% of the volunteers. The combined use of vaccines also did not show serious adverse events or cases of coronavirus infection after vaccination.
Authorization in Brazil
No registration requests for Sputnik Light were made in Brazil. The authorization process for emergency use Sputnik V has been facing difficulties in the country. Anvisa stated that it analyzed the data presented and indicated a series of information pending complementation or not presented by the company.
Since then, there have been no changes in the process, that is, the demand for data and additions made by Anvisa has not yet been answered by the laboratory. The application for authorization for the emergency use of the Sputnik vaccine was presented on March 25, 2021 by the União Química laboratory.
In June, Anvisa authorized the exceptional import of the vaccine, under a series of conditions. Among the main ones are the importation only of vaccines from factories inspected by Anvisa in Russia (Generium and Pharmstandard UfaVita); the obligation of batch-to-batch analysis that proves the absence of replicating viruses and other quality characteristics; and notification of serious adverse events within 24 hours. The Sputnik V vaccine is already approved in 70 countries, with a total population of more than 4 billion people
+ Until 2019, there were more people in prisons than on the Brazilian stock exchange
+ Aloe gel in the drink: see the benefits
+ Lemon-squeezing trick becomes a craze on social media
+ Chef playmate creates aphrodisiac recipe for Orgasm Day
+ Mercedes-Benz Sprinter wins motorhome version
+ Anorexia, an eating disorder that can lead to death
+ US agency warns: never wash raw chicken meat
+ Yasmin Brunet breaks the silence
+ Shark is captured in MA with the remains of youngsters missing in the stomach
+ See how much it costs to eat at the MasterChef judges’ restaurants
+ Auction of cars and motorcycles from Kombi to Nissan Frontier 0km